CureVac N.V. - Ordinary Shares (CVAC)
5.6000
+1.5300 (37.59%)
NASDAQ · Last Trade: Jun 12th, 6:56 PM EDT
Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · June 12, 2025
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · June 12, 2025
Via Benzinga · June 12, 2025

Shares of CureVac fell by 12.3% Wednesday afternoon. The pullback may stem from profit-taking after Tuesday's strong gains driven by rising concerns over U.S. respiratory illnesses.
Via Benzinga · January 8, 2025
BioNTech agreed to buy CureVac for $1.25 billion, expanding its mRNA cancer research and boosting its oncology pipeline.
Via Benzinga · June 12, 2025
Via Benzinga · June 12, 2025
Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session.
Via Chartmill · June 12, 2025
Under the terms of the deal, each CureVac share will be exchanged for approximately $5.46 in BioNTech American depositary shares.
Via Stocktwits · June 12, 2025
Discover the top movers in Thursday's pre-market session and stay informed about market dynamics.
Via Chartmill · June 12, 2025

The Trump administration terminated a nearly $600 million award to Moderna for developing an mRNA-based bird flu vaccine, ending a key Biden-era pandemic preparedness initiative. The cancellation introduces uncertainty into the nation's defense strategy against H5N1 avian influenza despite positive clinical trial results.
Via Benzinga · May 29, 2025
CureVac stock surged after reporting Q1 2025 results and a positive pipeline update. The biotech firm narrowed its operating loss, and cash is expected to fund operations through 2028.
Via Benzinga · May 20, 2025
The company reported revenue of €14.5 million for the fourth quarter, representing a decrease of €8.1 million from the corresponding period of 2023, and below an analyst estimate of €20.58, according to FinChat data.
Via Stocktwits · April 10, 2025
Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session.
Via Chartmill · March 28, 2025
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via Chartmill · March 28, 2025
Via Benzinga · March 28, 2025
CureVac's amended patent survives BioNTech's challenge as EPO upholds validity. A German court will decide on infringement in July 2025.
Via Benzinga · March 28, 2025
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
Via Chartmill · March 27, 2025

A Nevada dairy worker who initially tested positive for bird flu is currently experiencing mild symptoms, including "pink eye."
Via Benzinga · February 10, 2025

As the bird flu virus continues to spread through the United States, the Trump administration on Tuesday ordered all communications from the Centers for Disease Control and Prevention to stop.
Via Benzinga · January 24, 2025

According to the latest data from the Centers for Disease Control, the current bird flu outbreak has caused 67 human cases of bird flu in the U.S. and one death associated with the virus.
Via Benzinga · January 21, 2025

The CDC issued a health advisory Thursday recommending that hospitalized patients who have tested positive for influenza be tested for the bird flu virus within 24 hours.
Via Benzinga · January 16, 2025

CureVac shares have been volatile over the past week, gaining some 25%. The stock has seen increased trading volume following the U.S.'s first human death from H5N1 bird flu.
Via Benzinga · January 10, 2025

Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind.
Via Benzinga · January 8, 2025